We are live on ! Find out more
ORIA

Orion Biotech Opportunities Corp. Class A Ordinary Share
ORIA

Delisted

ORIA was delisted on the 28th of April, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Orion Biotech Opportunities Corp. Class A Ordinary Share in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 49 → 0 (-49)

100% less capital invested

Capital invested by funds: $145M → $0 (-$145M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 49

Holders
–
Holders Change
-49
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
49
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
-$13.4M
2
WCMNY
Westchester Capital Management (New York)
New York
-$9.74M
3
GCL
Glazer Capital LLC
New York
-$8.7M
4
MI
MMCAP International
Cayman Islands
-$8.18M
5
FTCM
Fir Tree Capital Management
New York
-$8.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Segantii Capital Management
Hong Kong
– -$1.54M -150,000 Closed
ACA
27
Arena Capital Advisors
California
– -$1.45M -141,317 Closed
SCM
28
Shaolin Capital Management
Florida
– -$1.25M -121,714 Closed
LP
29
LMR Partners
United Kingdom
– -$1.08M -105,100 Closed
DCM
30
Dupont Capital Management
Delaware
– -$1.02M -100,000 Closed
MSU
31
Mizuho Securities USA
New York
– -$1.01M -100,000 Closed
WAM
32
Weiss Asset Management
Massachusetts
– -$1.02M -100,000 Closed
CH
33
CVI Holdings
Delaware
– -$1.02M -99,375 Closed
SSA
34
Schonfeld Strategic Advisors
New York
– -$972K -94,843 Closed
WA
35
Whitebox Advisors
Minnesota
– -$767K -75,000 Closed
Marshall Wace
36
Marshall Wace
United Kingdom
– -$741K -72,475 Closed
VF
37
Virtu Financial
New York
– -$631K -61,730 Closed
MMRF
38
Michelson Medical Research Foundation
California
– -$519K -50,780 Closed
COPPSERS
39
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
– -$512K -49,945 Closed
LA
40
Linden Advisors
New York
– -$428K -41,814 Closed
Bank of Nova Scotia
41
Bank of Nova Scotia
Ontario, Canada
– -$409K -40,000 Closed
HighTower Advisors
42
HighTower Advisors
Illinois
– -$283K -27,688 Closed
PAMP
43
Polar Asset Management Partners
Ontario, Canada
– -$275K -26,900 Closed
HF
44
HRT Financial
New York
– -$204K -20,000 Closed
GAM
45
Gritstone Asset Management
Maryland
– -$167K -16,330 Closed
CC
46
Centiva Capital
New York
– -$108K -10,540 Closed
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
– -$102K -10,006 Closed
CS
48
Clear Street
New York
– -$1.23K -120 Closed
EC
49
Elequin Capital
New York
– -$51 -5 Closed
1
2

ORIA Hedge Fund Activity: Q2 2023 in Review

0 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) for Q2 2023, worth a combined $0 — down 100% from $145M a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of ORIA and 0 opened new positions — a net loss of 49 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Aristeia Capital, exiting entirely with an estimated $13.4M sold.

  • 0 institutional investors held Orion Biotech Opportunities Corp. Class A Ordinary Share (ORIA) as of Q2 2023, down from 49 in Q1 2023.
  • Funds reported $0 of Orion Biotech Opportunities Corp. Class A Ordinary Share stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Orion Biotech Opportunities Corp. Class A Ordinary Share positions in Q2 2023 and 49 closed out, a net change of -49 holders.
  • The largest Orion Biotech Opportunities Corp. Class A Ordinary Share seller in Q2 2023 was Aristeia Capital, an estimated $13.4M sold.

Based on aggregated 13F filings for Q2 2023.